secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2022-11-04T23:59:59+00:00
Accession:  0000886163-22-000129
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand completes OmniAb spin-off and merger with APAC; new President and CFO appointed
--------------------------------------------------------------------------------

- Completed separation and merger of OmniAb antibody discovery business with Avista Public Acquisition Corp. II (SPAC) on Nov 1, 2022.
- Ligand shareholders received 4.90007 New OmniAb shares per Legacy OmniAb share plus 0.75842 earnout shares.
- Post-transaction ownership: Ligand shareholders ~85%, APAC public ~1.1%, sponsor ~13.9% of New OmniAb.
- Three directors (Boyce, Cochran, Patel) and COO/General Counsel resigned; Korenberg appointed President/COO, Espinoza appointed CFO.
- Adopted amended severance plan and entered change-in-control severance agreements with new executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616322000129/0000886163-22-000129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616322000129/lgnd-20221101.htm
  HTML page:      https://secwatch.observer/filing/0000886163-22-000129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer